These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 38902241)

  • 41. Evaluation of RNAi therapeutics VIR-2218 and ALN-HBV for chronic hepatitis B: Results from randomized clinical trials.
    Gane E; Lim YS; Kim JB; Jadhav V; Shen L; Bakardjiev AI; Huang SA; Cathcart AL; Lempp FA; Janas MM; Cloutier DJ; Kaittanis C; Sepp-Lorenzino L; Hinkle G; Taubel J; Haslett P; Milstein S; Anglero-Rodriguez YI; Hebner CM; Pang PS; Yuen MF
    J Hepatol; 2023 Oct; 79(4):924-932. PubMed ID: 37290591
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Suppression of hepatitis B virus antigen production and replication by wild-type HBV dependently replicating HBV shRNA vectors in vitro and in vivo.
    Li B; Sun S; Li M; Cheng X; Li H; Kang F; Kang J; Dörnbrack K; Nassal M; Sun D
    Antiviral Res; 2016 Oct; 134():117-129. PubMed ID: 27591142
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis.
    Boni C; Janssen HLA; Rossi M; Yoon SK; Vecchi A; Barili V; Yoshida EM; Trinh H; Rodell TC; Laccabue D; Alfieri A; Brillo F; Fisicaro P; Acerbi G; Pedrazzi G; Andreone P; Cursaro C; Margotti M; Santoro R; Piazzolla V; Brunetto MR; Coco B; Cavallone D; Zhao Y; Joshi A; Woo J; Lau AH; Gaggar A; Subramanian GM; Massetto B; Fung S; Ahn SH; Ma X; Mangia A; Ferrari C
    Gastroenterology; 2019 Jul; 157(1):227-241.e7. PubMed ID: 30930022
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Small interfering RNA inhibits hepatitis B virus replication in mice.
    Giladi H; Ketzinel-Gilad M; Rivkin L; Felig Y; Nussbaum O; Galun E
    Mol Ther; 2003 Nov; 8(5):769-76. PubMed ID: 14599810
    [TBL] [Abstract][Full Text] [Related]  

  • 45. siRNA combinations mediate greater suppression of hepatitis B virus replication in mice.
    Li G; Fu L; Jiang J; Ping Y; Huang Y; Wang Y
    Cell Biochem Biophys; 2014 Jul; 69(3):641-7. PubMed ID: 24549857
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-term suppression of hepatitis B virus replication by short hairpin RNA expression using the scaffold/matrix attachment region-based replicating vector system pEPI-1.
    Jenke AC; Wilhelm AD; Orth V; Lipps HJ; Protzer U; Wirth S
    Antimicrob Agents Chemother; 2008 Jul; 52(7):2355-9. PubMed ID: 18474581
    [TBL] [Abstract][Full Text] [Related]  

  • 47. RNAi for treating hepatitis B viral infection.
    Chen Y; Cheng G; Mahato RI
    Pharm Res; 2008 Jan; 25(1):72-86. PubMed ID: 18074201
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication.
    Morrissey DV; Blanchard K; Shaw L; Jensen K; Lockridge JA; Dickinson B; McSwiggen JA; Vargeese C; Bowman K; Shaffer CS; Polisky BA; Zinnen S
    Hepatology; 2005 Jun; 41(6):1349-56. PubMed ID: 15880588
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Key elements of the RNAi pathway are regulated by hepatitis B virus replication and HBx acts as a viral suppressor of RNA silencing.
    Chinnappan M; Singh AK; Kakumani PK; Kumar G; Rooge SB; Kumari A; Varshney A; Rastogi A; Singh AK; Sarin SK; Malhotra P; Mukherjee SK; Bhatnagar RK
    Biochem J; 2014 Sep; 462(2):347-58. PubMed ID: 24902849
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Quantitative assessment of the antiviral potencies of 21 shRNA vectors targeting conserved, including structured, hepatitis B virus sites.
    Sun D; Rösler C; Kidd-Ljunggren K; Nassal M
    J Hepatol; 2010 Jun; 52(6):817-26. PubMed ID: 20400195
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Inhibition of hepatitis B virus and induction of hepatoma cell apoptosis by ASGPR-directed delivery of shRNAs.
    Ma J; Huang C; Yao X; Shi C; Sun L; Yuan L; Lei P; Zhu H; Liu H; Wu X; Ning Q; Zhou C; Shen G
    PLoS One; 2012; 7(10):e46096. PubMed ID: 23094023
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Highly specific delivery of siRNA to hepatocytes circumvents endothelial cell-mediated lipid nanoparticle-associated toxicity leading to the safe and efficacious decrease in the hepatitis B virus.
    Sato Y; Matsui H; Yamamoto N; Sato R; Munakata T; Kohara M; Harashima H
    J Control Release; 2017 Nov; 266():216-225. PubMed ID: 28986168
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Therapeutic effects of mesenchymal stem cells combined with short hairpin RNA on liver injury induced by hepatitis B virus infection.
    Liu D; Liu L; Wang L; Duan S; Song Y; Qu M; Gao N; Wu J; Zhang H; Wu H; Kong W; Yu B; Yu X
    Mol Med Rep; 2018 Jan; 17(1):1731-1741. PubMed ID: 29257255
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunomodulation and RNA interference alter hepatitis B virus-specific CD8 T-cell recognition of infected HepG2-NTCP.
    Kuipery A; Sanchez Vasquez JD; Mehrotra A; Feld JJ; Janssen HLA; Gehring AJ
    Hepatology; 2022 Jun; 75(6):1539-1550. PubMed ID: 34743340
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Does RNA interference provide new hope for control of chronic hepatitis B infection?
    Wilson R; Purcell D; Netter HJ; Revill PA
    Antivir Ther; 2009; 14(7):879-89. PubMed ID: 19918092
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The doses of plasmid backbone plays a major role in determining the HBV clearance in hydrodynamic injection mouse model.
    Wang X; Zhu J; Zhang Y; Li Y; Ma T; Li Q; Xu J; Xu L
    Virol J; 2018 May; 15(1):89. PubMed ID: 29783985
    [TBL] [Abstract][Full Text] [Related]  

  • 57. RNA interference inhibitors of hepatitis B virus.
    McCaffrey AP
    Ann N Y Acad Sci; 2009 Sep; 1175():15-23. PubMed ID: 19796073
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Co-delivery of Cas9 mRNA and guide RNAs edits hepatitis B virus episomal and integration DNA in mouse and tree shrew models.
    Yi J; Lei X; Guo F; Chen Q; Chen X; Zhao K; Zhu C; Cheng X; Lin J; Yin H; Xia Y
    Antiviral Res; 2023 Jul; 215():105618. PubMed ID: 37142191
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of cationic nanoparticles of biodegradable copolymers as siRNA delivery system for hepatitis B treatment.
    Wang J; Feng SS; Wang S; Chen ZY
    Int J Pharm; 2010 Nov; 400(1-2):194-200. PubMed ID: 20801205
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Viral Load Affects the Immune Response to HBV in Mice With Humanized Immune System and Liver.
    Dusséaux M; Masse-Ranson G; Darche S; Ahodantin J; Li Y; Fiquet O; Beaumont E; Moreau P; Rivière L; Neuveut C; Soussan P; Roingeard P; Kremsdorf D; Di Santo JP; Strick-Marchand H
    Gastroenterology; 2017 Dec; 153(6):1647-1661.e9. PubMed ID: 28851562
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.